ADTX vs ADXN

Aditxt, Inc. vs Addex Therapeutics Ltd — Valuation Comparison 2026

ADTX

Biotechnology
Aditxt, Inc.
Quality
3.1
out of 10
Value Trap
47
WARN
Price
$0.12
Last close
Models
4/13
Active
VS

ADXN

Biotechnology
Addex Therapeutics Ltd
Quality
5.5
out of 10
Value Trap
20
SAFE
Price
$6.65
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType ADTX Fair ValueADTX Upside ADXN Fair ValueADXN Upside
Bayesian DCF Intrinsic $0.15 -22.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $0.18 -7.6% $2.88 -58.8%
ML-RIV Intrinsic $13.22 +88.8%
Dynamic NAV Asset-Based $6.05 -8.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ADTX vs ADXN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ADTX vs ADXN — Which Stock Is More Undervalued?

ADXN scores higher with a 5.5/10 quality rating vs ADTX's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Aditxt, Inc. (ADTX) and Addex Therapeutics Ltd (ADXN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ADTX currently trades at $0.12 with a QOC of 3.1/10, while ADXN trades at $6.65 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).